The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Modelling treatment benefit for bexmarilimab (an anti-Clever-1 antibody and a novel macrophage checkpoint inhibitor) using phase I first-in-man trial data.
 
Petri Bono
Employment - Terveystalo
Stock and Other Ownership Interests - Faron Pharmaceuticals (I); Terveystalo; TILT Biotherapeutics
Consulting or Advisory Role - Faron Pharmaceuticals; Ipsen; MSD Oncology; Oncorena; TILT Biotherapeutics
Travel, Accommodations, Expenses - Faron Pharmaceuticals; MSD
 
Jussi Ekström
Employment - Kaiku Health
 
Matti K Karvonen
Employment - Faron Pharmaceuticals
Stock and Other Ownership Interests - Faron Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Faron Pharmaceuticals
 
Jami Mandelin
Employment - Faron Pharmaceuticals
Stock and Other Ownership Interests - Faron Pharmaceuticals
 
Jussi Koivunen
Employment - Faron Pharmaceuticals
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst)
Expert Testimony - AstraZeneca; Boehringer Ingelheim; Lilly; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer